Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isolagen has completed the pivotal efficacy portion of its Phase III clinical studies investigating the Isolagen Therapy for the treatment of nasolabial folds, or wrinkles.
Subscribe to our email newsletter
The last person in each study has completed the primary efficacy follow-up visit, and collation of this data has begun. The company anticipates that top-line efficacy and safety data analyses from the studies will be reported in August 2008.
Declan Daly, CEO of Isolagen, said: “The completion of the pivotal efficacy portion of our Phase III clinical studies is a major milestone for Isolagen. I commend the Isolagen team and our investigators for their efforts and look forward to announcing the data once it is un-blinded later this summer.”